Novel anti-c-MPL antibodies and uses thereof

Abstract

The present invention relates to a novel anti-c-MPL antibody and a use thereof, and more particularly, to an anti-c-MPL antibody having an effect of increasing platelet production and the number thereof by maturation of megakaryocytes in bone marrow, and a use thereof. The novel anti-c-MPL antibody (2R13) of the present invention has a longer half-life period than conventional therapeutic agents as a polymer material, and has the advantages of low autoantibody production and low immunogenicity as an antibody reagent. In addition, the present invention increases the platelet count in a patient suffering from immune thrombocytopenia that induces a chronic disease or complication, and thus can be used as a therapeutic agent for thrombocytopenia.